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Background and PurposeaaHyperglycemia after acute ischemic stroke (AIS) is associated 
with poor outcomes. However, there is no consensus as to the optimal method for glycemic con-
trol. We designed an insulin infusion protocol for aggressive glucose control and investigated 
its efficacy and safety. 
MethodsaaWe applied our protocol to patients within 48 hours after AIS or transient ischemic 
attack (TIA) with an initial capillary glucose level of between 100 and 399 mg/dL (5.6-22.2 
mmol/L). An insulin solution comprising 40 or 50 U of human regular insulin in 500 mL of 5% 
dextrose was administered for 24 hours. Capillary glucose was measured every 2 hours and the 
infusion rate was adjusted according to a nomogram with a target range of 80-129 mg/dL (4.4-
7.2 mmol/L). Changes in glucose and overall glucose levels during insulin infusion were analy-
zed according to the presence of diabetes or admission hyperglycemia (admission glucose 
>139 mg/dL or 7.7 mmol/L) by the generalized estimating equation method.   
ResultsaaThe study cohort comprised 115 consecutive patients. Glucose was significantly low-
ered from 160±57 mg/dL (8.9±3.2 mmol/L) at admission to 93±28 mg/dL (5.2±1.6 mmol/L) 
during insulin infusion (p<0.05). Laboratory hypoglycemia (capillary glucose <80 mg/dL or 4.4 
mmol/L) occurred in 91 (71%) patients, 11 (10%) of whom had symptomatic hypoglycemia. 
Although glucose levels were significantly lowered and maintained within the target range in all 
patients, overall glucose levels were significantly higher in patients with diabetes or hypergly-
cemia (p<0.05). 
ConclusionsaaOur insulin-infusion protocol was effective in glycemic control for patients 
with AIS or TIA. Further modification is needed to improve the efficacy and safety of this pro-
cedure, and tailored intervention should be considered according to glycemic status. 
  J Clin Neurol  2009;5:167-172
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Introduction 
 
Poststroke hyperglycemia (PSH) refers to elevation of blood 
glucose during the acute period of stroke and can occur in 
patients either with or without diabetes.
1 Depending on de-
finitions and study methodologies, between 20% and 50% of 
acute stroke patients have been shown to have hyperglyce-
mia at presentation.
2,3 Although the importance of PSH is not 
well established and the role of glycemic intervention in PSH 
remains unclear, many studies have suggested an association 
between PSH and poor clinical outcomes.
1,4-10 Intensive mo-
nitoring and control of physiologic parameters such as blood 
pressure and glucose is also cited as one of the benefits of 
acute stroke unit care.
11 Various methods of acute glycemic 
intervention for PSH have been reported and there is pre-
sently no consensus as to the optimal method. In some stu-
dies, the impact of PSH on clinical outcomes was apparent 
in nondiabetic hyperglycemia,
1,12 and one study found dif-
ferent therapeutic targets for diabetic and nondiabetic hyper-
glycemia.
13 The method or intensity of glycemic control may  
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also differ in patients with severe PSH. However, no study 
on acute glycemic intervention has addressed these issues. 
As a part of critical pathway development for the manage-
ment of patients with acute ischemic stroke (AIS) or transi-
ent ischemic attack (TIA), we developed a protocol for ag-
gressive glucose control in AIS patients by insulin infusion 
(AGAIN). We examined the efficacy and safety of our proto-
col according to the presence of diabetes and the severity of 
admission hyperglycemia. 
 
Methods 
 
From January 2007, we developed a protocol using conti-
nuous insulin infusion for acute glycemic control in patients 
with AIS or TIA. For protocol development, we hypothe-
sized that the glycemic response to insulin infusion would 
differ according to the presence of diabetes or the severity of 
hyperglycemia on admission. We therefore initially develop-
ed a single protocol for all patients, with the intention of am-
ending it according to the results of a pilot study. We pro-
spectively applied the single protocol to patients (aged 35-90 
years) with AIS or TIA within 48 hours of symptom onset 
who had an admission capillary glucose level of 100-399 
mg/dL (5.6-22.2 mmol/L). Patients with type 1 diabetes, dia-
betic ketoacidosis or nonketotic hyperosmolar state, heart 
failure, acute myocardial infarction, infection or high fever, 
severe anemia, renal failure, or other conditions that the duty 
neurologist judged inappropriate for the protocol were ex-
cluded. Patients with dementia, decreased consciousness, aph-
asia, severe dysarthria, and those who could not be admitted 
to the intensive care unit were also excluded. 
All enrolled patients fasted and were treated with our in-
sulin-infusion protocol for 24 hours in the intensive care unit. 
Insulin infusion after 24 hours was at the duty doctor’s dis-
cretion and data obtained after 24 hours were not included in 
this analysis. During insulin infusion, all premorbid antidia-
betic medications were temporarily discontinued. The initial 
protocol utilized an infusion of 500 mL of 5% dextrose with 
50 U of human regular insulin (Humulin R, Lilly Korea, Se-
oul, Korea) and 20 mmol of potassium chloride (KCl) start-
ing at the rate of 20 mL/hour (2.0 U/hour human regular in-
sulin). We subsequently modified our protocol to reduce the 
amount of insulin from 50 to 40 U (Table 1) due to concerns 
about hypoglycemia. Although the decision to apply the pro-
tocol was based on glucose levels on admission, baseline ca-
pillary glucose was also measured just before the start of in-
sulin infusion. 
Capillary glucose was measured during insulin infusion 
every 2 hours. The infusion rate was changed according to the 
dose adjustment nomogram of the protocol so as to maintain 
the capillary glucose at 80-129 mg/dL (4.4-7.2 mmol/L). We 
defined laboratory hypoglycemia as a capillary glucose level 
of less than 80 mg/dL (4.4 mmol/L), and defined symptoma-
tic hypoglycemia as the appearance of any of the symptoms 
of hypoglycemia (decreased consciousness, generalized weak-
ness, dizziness, and sweating). Vital signs and clinical status 
were monitored every hour and serum electrolytes including 
sodium and potassium were checked every 12 hours. 
All clinical data including National Institutes of Health 
Stroke Scale (NIHSS) score during admission and modified 
Rankin Scale (mRS) score at 3 months were prospectively 
registered on the Eulji Stroke Registry, which is incorporated 
with a Web-based stroke registry of Clinical Research Center 
for Stroke.
14 Data on glucose measurements and hypoglyce-
mia during insulin infusion were recorded prospectively in a 
separate AGAIN database using Microsoft Office Access 2003 
software. 
Based on the initial hypothesis, all patients were assigned 
to either the diabetic or nondiabetic group, and the hyper-
glycemic (admission capillary glucose >139 mg/dL or 7.7 
mmol/L) or normoglycemic (admission capillary glucose from 
100-139 mg/dL or 5.6-7.7 mmol/L) group. Efficacy was ev-
aluated for initial glycemic response at 2 hours after infusion, 
and the changes in glucose and overall glucose levels during 
insulin infusion. Safety was evaluated for the incidence of 
laboratory and symptomatic hypoglycemia. 
Student’s t-test for continuous variables and χ2 test for 
categorical variables were used for statistical analysis. Ch-
anges in glucose and overall glucose levels during insulin 
infusion was compared for capillary glucose measured every 
2 hours using the generalized estimating equation method 
with baseline capillary glucose as a covariate. SAS version 9.1 
was used for statistical analysis. Except where stated other-
wise, the data are presented as mean±SD values. 
Our protocol was developed to improve clinical practice 
rather than for academic purposes, and so we neither applied 
for the approval of the institutional review board of our hos-
Table 1. Intravenous insulin-infusion protocol 
Start dose 
40 U of regular insulin in 500 mL of 5% dextrose with 20 mEq of 
KCl at an infusion rate of 20 mL/hour (1.6 U/hour); check capil-
lary glucose every 2 hours 
Blood glucose level (mg/dL) Dose adjustment 
<80  Stop, then recheck in 30 minutes*
80-99  Decrease previous dose by 20%
100-129 No  change 
130-149  Increase previous dose by 10% 
150-199  Increase previous dose by 20% 
≥200  Increase previous dose by 40% 
*If symptomatic, give 30 mL of 50% dextrose. 
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pital nor obtained written informed consent to participate 
from the patients. 
 
Results 
 
From July 2007 to February 2009, 115 consecutive patients 
were treated with our insulin-infusion protocol. Baseline ch-
aracteristics are listed in Table 2. The mean age of the study 
cohort was 67 years, and 70 of them (60.9%) were male. One 
hundred (87%) patients had stroke, 47 (41%) had diabetes, 
and 57 (50%) had hyperglycemia on admission. Compared 
to admission glucose, baseline glucose increased by 15±12 
mg/dL (8.3±0.7 mmol/L) in 17 (15%) patients, decreased by 
41±42 mg/dL (2.3±2.3 mmol/L) in 87 (76%) patients, and 
remained the same in 11 (6%) patients. Baseline glucose was 
below 100 mg/dL (5.6 mmol/L) in 20 (17%) patients, of whom 
5 had diabetes and 7 had hyperglycemia on admission. 
Thirty-eight and 77 patients were treated with infusates in-
cluding 50 and 40 U of insulin, respectively. The glucose 
level during the 24 hours of insulin infusion was 93±28 
mg/dL (5.2±1.6 mmol/L), which was significantly lower than 
that measured on admission (p<0.05). Hypoglycemia occurr-
ed in 91 (79.1%) patients and symptomatic hypoglycemia oc-
curred in 11 (9.6%) patients, 6 (5.2%) of whom experienced 
recurrent symptomatic hypoglycemia. Insulin infusion was 
discontinued in four (3.5%) patients due to recurrent symp-
tomatic hypoglycemia in three and decreased consciousness 
by stroke progression with persistent hyperglycemia in one 
patient. Thirty (79%) of 38 patients treated with 50 U of in-
sulin and 61 (79%) of 77 patients treated with 40 U of insu-
lin suffered laboratory hypoglycemia. The initial glycemic 
response at 2 hours after insulin infusion was differed signi-
ficantly depending upon the presence of diabetes or hyper-
glycemia on admission (Table 3, Fig. 1). More patients with 
diabetes or hyperglycemia had capillary glucose levels above 
the target range, while more patients without diabetes or hy-
perglycemia had capillary glucose levels within or below the 
target range (p<0.05). The overall incidence of laboratory 
hypoglycemia was significantly higher in patients without hy-
perglycemia on admission (Table 3). 
One hundred and eleven patients completed the protocol 
and were analyzed for changes in glucose and overall glu-
cose levels during the 24 hours of insulin infusion, according 
to the presence of diabetes and hyperglycemia on admission 
Table 2. Baseline characteristics of the patients 
Characteristics  Values 
Number of patients  115 
Mean age, years (SD) 66.6  (12.8)
Male, n (%) 70  (60.9)
Diabetes, n (%) 47  (40.9)
Hypertension, n (%) 75  (65.2)
Mean HbA1c, % (SD) 6.5  (1.6) 
Admission NIHSS score, median (IQR) 4  (3-7)
Transient ischemic attack, n (%) 15  (13.0)
Treated with intravenous rt-PA, n (%) 15  (13.0)
Admission hyperglycemia,* n (%) 57  (49.6)
Mean admission capillary glucose, mg/dL (SD) 160.0  (56.9)
Mean baseline capillary glucose, mg/dL (SD) 131.6  (43.0)
*Admission capillary glucose >139 mg/dL (7.7 mmol/L). 
NIHSS: National Institutes of Health Stroke Scale, IQR: interqu-
artile range. 
 
Table 3. Capillary glucose at 2 hours after insulin infusion, and incidence of hyperglycemia
Diabetes  Admission hyperglycemia 
 
No (n=68)  Yes (n=47)  No (n=58)  Yes (n=57) 
Capillary glucose*† Below  TR‡ 22  (32) 12  (26) 19  (33) 15  (26) 
 Within  TR  42  (62) 23  (49) 36  (62) 29  (51) 
 Above  TR  04 (6)0 12  (26) 3  (5) 13  (23) 
Laboratory hypoglycemia§¶ 54  (79) 37  (79) 51  (88) 40  (70) 
Symptomatic hypoglycemia**  08 (12) 3  (6)  06 (10) 5  (9) 
Data are number of patients (% of patients in each column). 
*Results of capillary glucose measured at 2 hours after insulin infusion, †p<0.05 for comparisons between patients with and without dia-
betes or with and without hyperglycemia on admission, ‡Target range, 80-129 mg/dL (4.4-7.2 mmol/L), §p>0.1 for comparison between 
patients with and without diabetes, ¶p<0.05 for comparison between patients with and without hyperglycemia on admission, **p>0.1 for 
comparisons between patients with and without diabetes or with and without hyperglycemia on admission. 
TR: target range. 
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Fig. 1. The distribution of capillary glucose at 2 hours after insulin
infusion with regard to target range (TR).  
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(Table 4 and 5, Figs. 2 and 3). Glucose levels during insulin 
infusion changed significantly all groups (p<0.05 for a time 
effect). The interaction between change over time and groups 
was not significant (p>0.1 for an interaction effect between 
time and group), which means that changes in glucose levels 
over time were similar between comparison groups. Although 
mean glucose levels during insulin infusion were within the 
target range in all groups, the levels were significantly higher 
in patients with diabetes or hyperglycemia on admission (p< 
0.05 for a group effect). 
On clinical assessment, early neurological deterioration-
defined as an increase in the NIHSS score of 2 or more at 72 
hours after admission-occurred in 16 (13.9%) patients. The 
mRS score at 3 months was available in 97 (84%) patients, 
68 (70.1%) of whom had a favorable outcome (mRS score 
≥2). The occurrence of neurologic deterioration or favorable 
outcome at 3 months did not differ between patients with 
and without diabetes or with and without hyperglycemia on 
admission (p>0.1). 
 
Discussion 
 
Despite the high prevalence of PSH, evidence regarding the 
effects of glycemic control is still lacking. Although current 
guidelines agree that PSH is associated with poor outcomes, 
there is no consensus on the frequency of monitoring, thres-
holds for intervention, or method of glycemic control.
15,16 
Several investigators have recently reported on the efficacy 
and safety of glycemic control in AIS patients using different 
methods.
17-20 However, there is a wide variation in current 
clinical practice. We developed our own protocol and were 
able to achieve effective glycemic control in patients with 
AIS or TIA. Based on our initial hypothesis, we assessed the 
glycemic response to our protocol according to the presence 
Table 4. Levels of capillary glucose [mg/dL, mean (SD)] measur-
ed every 2 hours during insulin infusion with comparison accord-
ing to the presence of diabetes (n=111) 
Diabetes  Hours after starting 
insulin infusion  No (n=65)  Yes (n=46) 
p* 
02 94.3  (25.4) 109.4  (46.2) 
04 90.0  (22.6)  094.9 (34.2) 
06 92.1  (22.3)  095.0 (23.1) 
08 86.5  (14.7)  086.7 (17.8) 
10 85.7  (15.7)  088.2 (16.1) 
12 86.5  (15.0)  089.1 (18.3) 
14 85.0  (13.4)  091.4 (16.7) 
16 84.0  (13.9)  089.5 (15.7) 
18 85.2  (15.3)  090.3 (20.3) 
20 83.5  (16.3)  091.2 (25.0) 
22 84.6  (15.5)  093.0 (21.4) 
24 85.4  (17.7)  092.0 (26.5) 
†p<0.05
‡p<0.05
§p>0.1
*p values are for a group effect (†), time effect (‡), and interac-
tion effect between time and group (§) by analysis using the ge-
neralized estimating equation adjusted for baseline glucose. 
 
Table 5. Levels of capillary glucose [mg/dL, mean (SD)] measur-
ed every 2 hours during insulin infusion with comparison accord-
ing to the presence of hyperglycemia on admission (n=111) 
Admission hyperglycemia  Hours after starting 
insulin infusion  No (n=55)  Yes (n=56) 
p* 
02 91.6  (25.4) 109.2  (42.5) 
04 87.2  (28.7)  096.8 (26.6) 
06 90.5  (21.5)  096.0 (23.4) 
08 84.3  (14.9)  088.8 (16.8) 
10 84.4  (14.6)  089.1 (16.8) 
12 84.6  (15.5)  090.6 (17.0) 
14 85.6  (14.0)  089.6 (16.1) 
16 82.7  (12.6)  089.8 (16.1) 
18 82.3  (14.6)  092.2 (19.1) 
20 83.8  (18.4)  089.4 (22.3) 
22 84.0  (15.3)  092.2 (20.7) 
24 83.7  (19.4)  092.7(23.6) 
†p<0.05
‡p<0.05
§p>0.1
*p values are for a group effect (†), time effect (‡), and interac-
tion effect between time and group (§) by analysis using the ge-
neralized estimating equation adjusted for baseline glucose. 
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Fig. 2. Change of mean capillary glucose during insulin infusion ac-
cording to the presence of diabetes. 
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of diabetes or the severity of hyperglycemia measured on ad-
mission. 
There are several differences between our protocol and 
those described previously. For more stable glycemic control, 
all of our patients were ordered to fast during insulin infu-
sion and we used 5% dextrose solution instead of normal sa-
line. Unlike the method used in the United Kingdom Glu-
cose Insulin in Stroke Trial,
19 which was quite labor-inten-
sive, insulin dose adjustment was achieved by simply chang-
ing the infusion rate according to the nomogram. As a result, 
overall glucose levels were well maintained within the target 
range in all patients. Although laboratory hypoglycemia was 
quite common, symptomatic hypoglycemia occurred in less 
than 10% of our patients. The high prevalence of laboratory 
hypoglycemia can be attributed to several features of our study. 
The definition of laboratory hypoglycemia (<80 mg/dL or 4.4 
mmol/L) was more rigorous than that of other studies, in which 
it was defined as less than 54-72 mg/dL (3-4 mmol/L).
17-19 In 
fact, despite the high incidence of laboratory hypoglycemia, 
the rate of symptomatic hypoglycemia in our study was com-
parable to those reported in other studies.
17-19 
The severity of hyperglycemia in our study patients is ano-
ther consideration. We did not apply our protocol to patients 
who could not communicate properly due to altered con-
sciousness, aphasia, or severe dysarthria, thus excluding pa-
tients with moderate-to-severe stroke. As a result, most pa-
tients had only mild-to-moderate hyperglycemia on admis-
sion. We also included TIA patients in whom glucose might 
decrease rapidly and significantly without insulin infusion as 
symptoms were resolving. A spontaneous decrease in glucose 
levels between admission and baseline measurements was also 
common, being observed in 76% of patients. Because the 
decision to apply the insulin-infusion protocol was based on 
the level of blood glucose at admission, insulin infusion was 
carried out even though the baseline glucose was less than 
100 mg/dL (5.6 mmol/L), which occurred in 17% of study 
patients. Inclusion of patients who had admission glucose le-
vels that were already within the target range (i.e., 100-130 
mg/dL or 5.6-7.2 mmol/L) should also be considered. We 
included those patients because late hyperglycemia can oc-
cur more than 48 hours after stroke.
5 
Fasting during insulin infusion is another important factor. 
As mentioned above, all patients in our study fasted during 
insulin infusion because we thought that fasting for a short 
period after acute stroke is tolerable and can offer more st-
able glycemic control. Fasting is not mandatory in the gene-
ral management of acute stroke if the patient does not suffer 
dysphagia. However, neurological deficit is unstable in the 
acute period and oral intake should be cautiously monitored 
because of the risk of aspiration. Although oral intake might 
have reduced the occurrence of hypoglycemia, it could also 
have caused fluctuations in blood glucose, thus rendering 
glycemic control more difficult and complicated. 
In general, selecting the appropriate target range is impor-
tant for optimizing the efficacy and safety of treatment. There 
is currently no consensus on these issues for glycemic con-
trol in acute stroke patients.
4 In an animal experiment, glu-
cose levels exhibited a U-shaped association with cortical 
necrosis and total infarction, with a nadir for cerebral necro-
sis in the 108-126 mg/dL (6-7 mmol/L) range.
21 In humans, 
most studies addressing the association between glucose 
levels and poor outcome used predefined and arbitrary th-
resholds of 108-150 mg/dL (6-8.3 mmol/L).
5-10 A meta-an-
alysis revealed an association between admission glucose 
levels higher than 110-126 mg/dL (6.1-7.0 mmol/L) and in-
creased risk of mortality in nondiabetic ischemic stroke pa-
tients. A recent study found that the optimal cutoff level for 
poor outcome at 3 months was 155 mg/dL (8.5 mmol/L).
22 
In glycemic intervention studies after AIS, the lower th-
resholds for inclusion ranged from 108 to 170 mg/dL (6.0-
9.4 mmol/L) and target ranges were usually between 70 and 
130 mg/dL (3.9 and 7.2 mmol/L).
17-19 This variability was 
attributable to differences in patient populations (differences 
in stroke subtypes, diabetic population, and time window af-
ter stroke). In a large study involving 1,259 patients with 
AIS, hyperglycemia was associated with worse clinical out-
comes only in nonlacunar stroke.
23 Because hyperglycemia 
decreases over time after stroke,
24 including patients visiting 
during the late time window may influence the threshold 
level for poor outcomes. 
There is evidence that the benefit of glycemic control or 
the optimal range of glucose concentration differs between 
diabetic and nondiabetic hyperglycemia.
1,13 To address this 
issue, different approaches using different regimens and com-
parative analysis according to the patient characteristics are 
needed. In our analyses we found that the treatment effect of 
our protocol did not differ with the presence of diabetes and 
hyperglycemia on admission. Capillary glucose levels during 
insulin infusion decreased significantly and were maintained 
within the target range. However, although the difference was 
small, overall glucose levels during insulin infusion were 
persistently higher in patients with diabetes or hyperglyce-
mia on admission. Considering that most patients had mild-
to-moderate hyperglycemia, this finding suggests that pa-
tients with severe diabetic hyperglycemia exhibit a different 
glycemic response. 
More intensive control may be needed for patients treated 
with thrombolysis. Several studies involving patients treated 
with thrombolytic therapy have demonstrated a profound ef-
fect of hyperglycemia on outcomes.
25-27 As mentioned above,  
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the time window after stroke should also be considered. Un-
like other studies,
17-20 we extended the treatment time win-
dow to 48 hours after symptom onset. It has been shown that 
PSH is prolonged despite current guidelines-based treatment, 
and two hyperglycemic phases were identified: an early hy-
perglycemia phase within the first 8 hours and a later phase 
48-88 hours poststroke.
5 The timing of glycemic control after 
stroke may not necessarily follow conventional windows for 
other acute therapies, and patients may be potential candi-
dates for benefit at 12-24 hours after acute stroke. 
In conclusion, our insulin-infusion protocol was feasible 
and could achieve successful glycemic control in AIS or TIA 
patients with mild-to-moderate hyperglycemia. However, la-
boratory hypoglycemia was common, and differed signifi-
cantly between patients with and without diabetes or admis-
sion hyperglycemia during treatment. To improve the effi-
cacy and safety of this protocol, further modification is need-
ed and tailored intervention should be considered, especially 
for patients with severe diabetic hyperglycemia. 
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